FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2987174857> ?p ?o ?g. }

• W2987174857 endingPage "5704" @default.
• W2987174857 startingPage "5704" @default.
• W2987174857 abstract "Abstract Extramedullary myeloma (EMM) is defined by the presence of plasma cells outside the bone marrow in a patient with multiple myeloma (MM) (Touzeau & Moreau, 2016). EMM is by itself a rare entity with cases involving central nervous system (CNS) being rarer, it has an estimated incidence of 1-1.8% of all MM cases (Majd et al, 2015). Its presentation in comparison to classical MM has an adverse prognosis including a shorter progression free survival (PFS) (Gozzetti et al, 2015) and overall survival (OS) with a mean life expectancy of 1.5-6 months (Majd et al, 2015). Currently there are not international treatment guidelines for this disease. The aim of this report is to illustrate our experience at a single institution in Mexico, presenting five cases of CNS-EMM treated with proteasome inhibitor (carfilzomib) in combination with thalidomide, dexamethasone plus radiotherapy. The patient's characteristics and the treatment regimen are shown in table 1 and 2. Within three months, following the criteria to the international multiple myeloma working group (IMMWG), all five patients accomplished a positive response (one partial response [PR] four very good partial responses [VGPR]), at sixth months two patients improved their response from previously PR to a VGPR and from VGPR to complete response (CR), one sustained its VGPR and after this period of time two patients had progressive disease (PD) and died due to infectious complications. After the tenth month a third patient also died of infectious complications. By the end of this report two patients still alive, one is being evaluated for autologous stem cell transplantation (ASCT) and the other one wasn't eligible according to European Group for Blood and Marrow Transplantation (EBMT) risk score and will continue treatment without ASCT. Previously reported cases in the literature with old chemotherapy regimens shown to have median survival of 1.5 months (Petersen et al 1999), nowadays the recommended therapy is based on triplet induction therapy followed by high-dose melphalan/ASCT, a triplet consolidation therapy and maintenance treatment with lenalidomide (Touzeau & Moreau, 2016); so far there is no evidence of proteasome inhibitors penetrating the blood brain barrier (Nooka et al, 2013) and this might be the reason why the literature strongly recommends the use of lenalidomide as this one does penetrate into the CSF after oral administration (Muscal et al, 2012), we did not use lenalidomide due to the high monetary cost of the treatment but instead we use thalidomide in combination with carfilzomib and dexamethasone with improved OS in three of our five patients (VGPR + CR). Despite the small number of patients presented in this report and the lack of cytogenetics or FISH information, we think this might be a good therapeutic approached in patients with CNS-EMM, especially in those scenarios with not accessible resources or absence of clinical trials. Further studies evaluating the addition of monoclonal antibodies (daratumumab, elotuzumab) need to be done in order to improve the OS and PFS in this group of patients. Disclosures No relevant conflicts of interest to declare." @default.
• W2987174857 created "2019-11-22" @default.
• W2987174857 creator A5009024049 @default.
• W2987174857 creator A5010146958 @default.
• W2987174857 creator A5014726277 @default.
• W2987174857 creator A5017254917 @default.
• W2987174857 creator A5021568478 @default.
• W2987174857 creator A5026662740 @default.
• W2987174857 creator A5027096545 @default.
• W2987174857 creator A5031001449 @default.
• W2987174857 creator A5032100196 @default.
• W2987174857 creator A5033755112 @default.
• W2987174857 creator A5039098626 @default.
• W2987174857 creator A5059448027 @default.
• W2987174857 creator A5061367144 @default.
• W2987174857 creator A5071764652 @default.
• W2987174857 creator A5073679135 @default.
• W2987174857 creator A5083594117 @default.
• W2987174857 date "2016-12-02" @default.
• W2987174857 modified "2023-09-27" @default.
• W2987174857 title "Report of 5 Cases of Extramedullary Myeloma with Central Nervous System Involvement Treated with a Combination of Carfilzomib/Thalidomide/Dexamethasone As a First Line Treatment at a Single Institution in Mexico" @default.
• W2987174857 doi "https://doi.org/10.1182/blood.v128.22.5704.5704" @default.
• W2987174857 hasPublicationYear "2016" @default.
• W2987174857 type Work @default.
• W2987174857 sameAs 2987174857 @default.
• W2987174857 citedByCount "2" @default.
• W2987174857 countsByYear W29871748572020 @default.
• W2987174857 countsByYear W29871748572022 @default.
• W2987174857 crossrefType "journal-article" @default.
• W2987174857 hasAuthorship W2987174857A5009024049 @default.
• W2987174857 hasAuthorship W2987174857A5010146958 @default.
• W2987174857 hasAuthorship W2987174857A5014726277 @default.
• W2987174857 hasAuthorship W2987174857A5017254917 @default.
• W2987174857 hasAuthorship W2987174857A5021568478 @default.
• W2987174857 hasAuthorship W2987174857A5026662740 @default.
• W2987174857 hasAuthorship W2987174857A5027096545 @default.
• W2987174857 hasAuthorship W2987174857A5031001449 @default.
• W2987174857 hasAuthorship W2987174857A5032100196 @default.
• W2987174857 hasAuthorship W2987174857A5033755112 @default.
• W2987174857 hasAuthorship W2987174857A5039098626 @default.
• W2987174857 hasAuthorship W2987174857A5059448027 @default.
• W2987174857 hasAuthorship W2987174857A5061367144 @default.
• W2987174857 hasAuthorship W2987174857A5071764652 @default.
• W2987174857 hasAuthorship W2987174857A5073679135 @default.
• W2987174857 hasAuthorship W2987174857A5083594117 @default.
• W2987174857 hasBestOaLocation W29871748571 @default.
• W2987174857 hasConcept C126322002 @default.
• W2987174857 hasConcept C141071460 @default.
• W2987174857 hasConcept C2776364478 @default.
• W2987174857 hasConcept C2777478702 @default.
• W2987174857 hasConcept C2779609412 @default.
• W2987174857 hasConcept C2780108899 @default.
• W2987174857 hasConcept C2780401358 @default.
• W2987174857 hasConcept C2781413609 @default.
• W2987174857 hasConcept C71924100 @default.
• W2987174857 hasConceptScore W2987174857C126322002 @default.
• W2987174857 hasConceptScore W2987174857C141071460 @default.
• W2987174857 hasConceptScore W2987174857C2776364478 @default.
• W2987174857 hasConceptScore W2987174857C2777478702 @default.
• W2987174857 hasConceptScore W2987174857C2779609412 @default.
• W2987174857 hasConceptScore W2987174857C2780108899 @default.
• W2987174857 hasConceptScore W2987174857C2780401358 @default.
• W2987174857 hasConceptScore W2987174857C2781413609 @default.
• W2987174857 hasConceptScore W2987174857C71924100 @default.
• W2987174857 hasIssue "22" @default.
• W2987174857 hasLocation W29871748571 @default.
• W2987174857 hasOpenAccess W2987174857 @default.
• W2987174857 hasPrimaryLocation W29871748571 @default.
• W2987174857 hasRelatedWork W1999964913 @default.
• W2987174857 hasRelatedWork W2013163224 @default.
• W2987174857 hasRelatedWork W2088313945 @default.
• W2987174857 hasRelatedWork W2112489854 @default.
• W2987174857 hasRelatedWork W2427804748 @default.
• W2987174857 hasRelatedWork W2606454205 @default.
• W2987174857 hasRelatedWork W2738602720 @default.
• W2987174857 hasRelatedWork W2783534173 @default.
• W2987174857 hasRelatedWork W3211465325 @default.
• W2987174857 hasRelatedWork W4241469660 @default.
• W2987174857 hasVolume "128" @default.
• W2987174857 isParatext "false" @default.
• W2987174857 isRetracted "false" @default.
• W2987174857 magId "2987174857" @default.
• W2987174857 workType "article" @default.